J&J Beats Q4 Earnings Forecasts, But 2025 Sales Projections Disappoint
J&J beat Q4 2024 earnings forecasts but issued a disappointing 2025 sales outlook below analyst expectations. Strong pharmaceutical and medical device performance was offset by competitive pressures and looming patent expirations.
J&J Beats Q4 Earnings Forecasts, But 2025 Sales Projections Disappoint Read More »